Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) FCF Margin (2016 - 2025)

Traws Pharma's FCF Margin history spans 14 years, with the latest figure at 218.77% for Q2 2025.

  • Quarterly results put FCF Margin at 218.77% for Q2 2025, up 1706544.0% from a year ago — trailing twelve months through Dec 2025 was 651.79% (up 1253051.0% YoY), and the annual figure for FY2025 was 744.44%, up 1405202.0%.
  • FCF Margin for Q2 2025 was 218.77% at Traws Pharma, up from 9538.6% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 218.77% in Q2 2025 to a low of 20133.33% in Q3 2024.
  • The 5-year median for FCF Margin is 7755.89% (2022), against an average of 8744.54%.
  • The sharpest move saw FCF Margin plummeted -1229298bps in 2024, then surged 1706544bps in 2025.
  • Year by year, FCF Margin stood at 7616.07% in 2021, then grew by 9bps to 6935.71% in 2022, then dropped by -14bps to 7910.71% in 2023, then grew by 9bps to 7214.29% in 2024, then skyrocketed by 97bps to 218.77% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 218.77%, 9538.6%, and 7214.29% for Q2 2025, Q1 2025, and Q4 2024 respectively.